http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101842279-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-437 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-685 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-685 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-66 |
| filingDate | 2012-03-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2018-03-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2018-03-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-101842279-B1 |
| titleOfInvention | Injectable composition of irinotecan with improved stability |
| abstract | The present invention relates to a composition for injection which improves neutral solution and blood stability of irinotecan, which is an anticancer agent, and which forms ion pairs with phosphatidylserine having a short chain or medium chain fatty acid chain. The composition thus prepared exhibited remarkably improved stability of neutral phosphate buffer and active form in blood when compared with a commercially available pharmaceutical composition. |
| priorityDate | 2012-03-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 41.